Skip to main content
Article
Germline Mutations in Patients With Early-Onset Prostate Cancer.
Frontiers in Oncology
  • Tang Tang
  • Xintao Tan
  • Ze Wang
  • Shuo Wang
  • Yapeng Wang
  • Jing Xu
  • Xiajie Wei
  • Dianzheng Zhang, Philadelphia College of Osteopathic Medicine
  • Qiuli Liu
  • Jun Jiang
Document Type
Article
Publication Date
1-1-2022
Abstract

Objective: To investigate the inherited mutations and their association with clinical features and treatment response in young-onset prostate cancer patients.

Method: Targeted gene sequencing on 139 tumor susceptibility genes was conducted with a total of 24 patients diagnosed with PCa under the age of 63 years old. Meanwhile, the related clinical information of those patients is collected and analyzed.

Results: Sixty-two germline mutations in 45 genes were verified in 22 patients.

Conclusion: Mutations in DRGs are more prevalent in early-onset PCa with advanced clinical stages, and these patients had shorter progression-free survival. ADT Combined with either radiotherapy or chemotherapy may be effective in treating PCa caused by HRR-related gene mutations.

PubMed ID
35734583
Comments

This article was published in Frontiers in Oncology, Volume 12.

The published version is available at https://doi.org/10.3389/fonc.2022.826778.

Copyright © 2022 Tang, Tan, Wang, Wang, Wang, Xu, Wei, Zhang, Liu and Jiang. CC-BY 4.0.

Citation Information
Tang Tang, Xintao Tan, Ze Wang, Shuo Wang, et al.. "Germline Mutations in Patients With Early-Onset Prostate Cancer." Frontiers in Oncology Vol. 12 (2022)
Available at: http://works.bepress.com/dianzheng_zhang/116/